TY - JOUR
T1 - Electronic Patient-Reported Outcome–Based Symptom Management Versus Usual Care After Lung Cancer Surgery
T2 - Long-Term Results of a Multicenter, Randomized, Controlled Trial
AU - Dai, Wei
AU - Wang, Yaqin
AU - Liao, Jia
AU - Wei, Xing
AU - Dai, Zhen
AU - Xu, Wei
AU - Liu, Yangjun
AU - Wang, Xin Shelley
AU - Pompili, Cecilia
AU - Yu, Hongfan
AU - Pu, Yang
AU - Zhao, Yuqian
AU - Cao, Bangrong
AU - Wang, Qifeng
AU - Feng, Wenhong
AU - Zhang, Yuanqiang
AU - Liu, Fang
AU - Deng, Yuanle
AU - Zhou, Jin
AU - Li, Juan
AU - Xie, Shaohua
AU - Xiang, Run
AU - Wang, Xiang
AU - Tian, Bo
AU - Yang, Xiaozun
AU - Hu, Bin
AU - Liu, Xiaoqin
AU - Xie, Tianpeng
AU - Yang, Xiaojun
AU - Zhuang, Xiang
AU - Qiao, Guibin
AU - Li, Qiang
AU - Shi, Qiuling
N1 - Publisher Copyright:
© 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/6/20
Y1 - 2024/6/20
N2 - Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported superior symptom control of electronic patient-reported outcome (ePRO)–based symptom management after lung cancer surgery for up to 1 month postdischarge. Here, we present the long-term results (1-12 months) of this multicenter, randomized trial, where patients were assigned 1:1 to receive postoperative ePRO-based symptom management or usual care daily postsurgery, twice weekly postdischarge until 1 month, and at 3, 6, 9, and 12 months postdischarge. Long-term patient-reported outcomes were assessed with MD Anderson Symptom Inventory-Lung Cancer module. Per-protocol analyses were performed with 55 patients in the ePRO group and 57 in the usual care group. At 12 months postdischarge, the ePRO group reported significantly fewer symptom threshold events (any of the five target symptom scored ≥4; median [IQR], 0 [0-0] v 0 [0-1]; P 5 .040) than the usual care group. From 1 to 12 months postdischarge, the ePRO group consistently reported significantly lower composite scores for physical interference (estimate, –0.86 [95% CI, –1.32 to –0.39]) and affective interference (estimate, –0.70 [95% CI, –1.14 to –0.26]). Early intensive ePRO-based symptom management after lung cancer surgery reduced symptom burden and improved functional status for up to 1 year postdischarge, supporting its integration into standard care.
AB - Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported superior symptom control of electronic patient-reported outcome (ePRO)–based symptom management after lung cancer surgery for up to 1 month postdischarge. Here, we present the long-term results (1-12 months) of this multicenter, randomized trial, where patients were assigned 1:1 to receive postoperative ePRO-based symptom management or usual care daily postsurgery, twice weekly postdischarge until 1 month, and at 3, 6, 9, and 12 months postdischarge. Long-term patient-reported outcomes were assessed with MD Anderson Symptom Inventory-Lung Cancer module. Per-protocol analyses were performed with 55 patients in the ePRO group and 57 in the usual care group. At 12 months postdischarge, the ePRO group reported significantly fewer symptom threshold events (any of the five target symptom scored ≥4; median [IQR], 0 [0-0] v 0 [0-1]; P 5 .040) than the usual care group. From 1 to 12 months postdischarge, the ePRO group consistently reported significantly lower composite scores for physical interference (estimate, –0.86 [95% CI, –1.32 to –0.39]) and affective interference (estimate, –0.70 [95% CI, –1.14 to –0.26]). Early intensive ePRO-based symptom management after lung cancer surgery reduced symptom burden and improved functional status for up to 1 year postdischarge, supporting its integration into standard care.
UR - http://www.scopus.com/inward/record.url?scp=85194318714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85194318714&partnerID=8YFLogxK
U2 - 10.1200/JCO.23.01854
DO - 10.1200/JCO.23.01854
M3 - Article
C2 - 38574304
AN - SCOPUS:85194318714
SN - 0732-183X
VL - 42
SP - 2126
EP - 2131
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 18
ER -